In the Claims

Please amend the claims as follows:

1. (Original) A nucleic acid molecule encoding a MUC-1 derivative which is capable of raising an immune response *in vivo*, said response being capable of recognising a MUC-1 expressing tumour, wherein the nucleic acid has a RSCU value for the non-repeat region of at least 0.6 and has a level of identity of less than 85% in comparison with the MUC-1 VNTR nucleotide sequence shown in Figure 9, with respect to the corresponding non-repeat region of wild type MUC-1.

2. (Original) A nucleic acid molecule as claimed in claim 1 wherein the RSCU is at least 0.65%.

3. (Original) A nucleic acid molecule as claimed in claim 1 wherein the identity is less than 80%.

4. (Original) A nucleic acid molecule encoding a MUC-1 derivative as claimed in claim 1 having less than 15 perfect repeat units.

5. (Original) A nucleic acid molecule as claimed in claim 4 having no perfect repeats.

6. (Previously presented) A nucleic acid molecule as claimed in claim 1 of which is devoid of a signal sequence.

7. (Previously presented) A nucleic acid molecule as claimed in claim 1 that encodes one or more of the sequences from the group: FLSFHISNL; NSSLEDPSTDYYQELQRDISE; and NLTISDVSV.

8. (Previously presented) A nucleic acid molecule as claimed in claim 1 additionally comprising a heterologous sequence that encodes a T-Helper epitope.

9. (Previously presented) A nucleic acid molecule as claimed in claim 1 that is a DNA molecule.

10. (Previously presented) A plasmid comprising the DNA molecule of Claim 1.

11. (Previously presented) A pharmaceutical composition comprising a nucleic acid as claimed in claim 1 and a pharmaceutical acceptable excipient, diluent or carrier.

12. (Previously presented) A pharmaceutical composition as claimed in claim 11 wherein the carrier is a microparticle.

13. (Original) A pharmaceutical composition as claimed in claim 12 wherein the microparticle is gold.

14. (Previously presented) A pharmaceutical composition as claimed in claim 11 additionally comprising an adjuvant.

15. (Cancelled).

16. (Currently amended) A method according to claim 17, wherein said ~~of treating or preventing MUC-1 expressing tumours comprising administering a medicament comprising a~~ nucleic acid molecule is in a pharmacetical composition comprising a pharmaceutically acceptable excipient, diluent or carrer ~~as claimed in claim 1~~.

17. (Currently amended) A method of treating ~~or preventing~~ MUC-1 over-expressing tumours in a mammal, comprising administering ~~a safe and effective amount of~~ a nucleic acid ~~as claimed in claim 1~~ molecule encoding a MUC-1 protein that raises an immune response to MUC-1 *in vivo*, said immune response recognising a MUC-1 over-expressing tumour, wherein the non-repeat region of the nucleic acid molecule has a Relative Synonymous Codon Usage (RSCU) value of at least 0.6 and has a level of nucleotide identity of less than 85% in comparison with the non-repeat region of SEQ ID NO:16, where

said nucleic acid molecule is administered in an amount effective to raise an immune response to MUC-1 .

18. (Previously presented) A medicament comprising a plasmid as claimed in claim 10.

19-20. (Cancelled).

21. (New) A method according to claim 17 wherein said nucleic acid molecule encodes a MUC-1 protein having fewer than 15 perfect repeat units.

22. (New) A method according to claim 17 wherein said nucleic acid molecule encodes a MUC-1 protein having no perfect repeat units.

23. (New) A method according to claim 17 wherein said nucleic acid molecule additionally comprises a heterologous sequence that encodes a T-Helper epitope.

24. (New) A method according to claim 16 wherein said pharmaceutical composition additionally comprises an adjuvant.

25. (New) A method according to claim 17 wherein said nucleic acid molecule is contained within a plasmid.

26. (New) A method according to claim 17 wherein said nucleic acid molecule comprises a sequence selected from SEQ ID NO:13 and SEQ ID NO:14.